Clinical trialPhase 2Terminated
Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer
A Phase II Study of Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer
- Outcome
- Stopped earlyClosed due to delay by GSK (Other)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- August 2010
- Expected end
- October 2011
- Enrollment
- 2 participants
- Sites
- 1
- Primary outcomes
- Response Rate by RECIST Criteria.
- Sponsor
- Other
- Results posted
- 2015-06-09
- Last update
- 9 June 2015
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
To determine the response rate and survival of gemcitabine and pazopanib in patients with metastatic pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
To determine the response rate by RECIST criteria. To determine the progression free survival. To determine the median survival and overall survival at one year.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Response Rate by RECIST Criteria. [Follow-up was approximately 9 weeks]. Number, percentage of participants. Arm 1 (Gemcitabine & Pazopanib) (n=1): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Progression-free Survival (PFS) [Follow-up was approximately 9 weeks]. Number, weeks. Arm 1 (Gemcitabine & Pazopanib) (n=1): 8.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Median Survival [Length of follow-up was 35 weeks]. Median, weeks (Full Range). Arm 1 (Gemcitabine & Pazopanib) (n=2): 34 (33 to 35).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Survival [1 year]. Number, participants. Arm 1 (Gemcitabine & Pazopanib) (n=2): 0.